Platinum (II) N‐heterocyclic carbene complexes: Synthesis, characterization and cytotoxic properties

Abstract

Platinum (II) complexes bearing N‐heterocyclic carbene (NHC) ligands have been widely used in catalytic chemistry, but there are very few reports of biological properties of this type of complexes. A series of [PtCl2(NHC)(PEt3)] complexes were synthesized. The structures of all compounds were characterized by 1H‐NMR, 13C‐NMR, IR and elemental analysis techniques, which supported the proposed structures. The single crystal structures of complexes 1a and 1e were determined. The title complexes show slightly distorted square‐planar coordination around the platinum (II) metal center. The cytotoxic properties of the platinum (II)–NHC complexes have been assessed in various human cancer lines, including cisplatin‐sensitive and resistant cells. IC50 values of these four complexes were determined by the MTS‐based assay on three human cell lines—brain (SHSY5Y), colon (HTC116) and liver (HEP3B). These complexes have been highlighted cancer therapeutic agent with unique structures and functions.

Cyanopropyl functionalized benzimidazolium salts and their silver N‐heterocyclic carbene complexes: Synthesis, antimicrobial activity, and theoretical analysis

“…[ 5,6 ] In recent years, metal‐N‐heterocyclic carbene (NHC) complexes have shown promise in biomedical applications, including as antimicrobial, anticancer, and antitumor (palladium‐, copper‐, silver‐, gold‐, ruthenium‐, rhodium‐, and platinum‐NHC) agents. [ 7–36 ] The efficacy of a silver‐based drug appears to be linked to its bioavailability [ 13,37 ] which is affected by, for example, its solubility and the presence of biological ligands and halides. The release rate of silver from a prodrug is linked to the ancillary ligand, and as NHCs are strong σ donors, silver‐NHCs can have a slow silver release rate.…”